MoneyWorks4Me

Samrat Pharmachem informs about board meeting

30 Sep 2019 Evaluate

Samrat Pharmachem has informed that the meeting of the Board of Directors of the Company is scheduled on 14/11/2019 to consider and approve the Un-Audited Financial Results of the Company under Indian Accounting Standards (Ind-As) for the quarter ended September 30, 2019.

The above information is a part of company’s filings submitted to BSE.

Samrat Pharmachem Share Price

231.20 -9.15 (-3.81%)
14-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1924.90
Dr. Reddys Labs. 1202.00
Cipla 1450.00
Lupin 2235.00
Zydus Lifesciences 1140.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: